Patients who used the SGLT2 inhibitors had a significantly lower risk of heart failure than those without SGLT2 inhibitors (RR 0.43, 95% CI 0.24, 0.79, P = 0.0063, I2 = 75%, PI 0.07, 2.64) (Figure 3A). This evidence concerns the gene SLC5A2 and heart failure.